ERBB2 and glioblastoma: Specifically, certain immunosuppressive molecules were observed to be increased after CAR-T infusion, highlighting the constraints posed by the immunosuppressive microenvironment on CAR-T cell therapy.[129] A clinical trial testing the feasibility and safety of allogeneic CAR-T cell therapy for the treatment of recurrent unresectable GBM has shown that a transient anti-tumor effect was achieved in some patients.[130] Another research investigation assessed the efficacy of CAR-modified virus-specific T-cell therapy in treating individuals with HER2-positive GBM.